Abstract
Cisplatin, cis-diamminedichloroplatinum (II), is one of the most widely used anticancer drugs. The main cellular target of cisplatin is DNA, where the platinum atom is able to form covalent bonds with the N7 of purines. It is commonly accepted that there is a direct attack of cisplatin on DNA. But it should be noted that, inside cells, free purine bases, which can react with cisplatin, are also available. Free bases have many functional roles, not least the constitution of building blocks for the synthesis of new DNA and RNA molecules. For this reason, under physiological conditions, the erroneous insertion of platinated bases in the synthesized nucleic acids could compete with direct DNA/RNA platination. Moreover, due to the lower sterical hindrance offered by single nucleobases with respect to nucleic acids, platination is expected to be even easier for free purines with respect to DNA and RNA. We have recently shown, for the first time, that platinated DNA can be formed in vitro by Taq DNA polymerase promoted incorporation of platinated purines. Cytotoxicity tests with [Pt(dien)(N7-G)], dien = diethylenetriamine, G = 5′-dGTP, 5′-dGDP, 5′-GMP, 5′-dGMP, GUO, dGUO, complexes on HeLa cancer cells support this hypothesis of the relative cytotoxicity of [Pt(dien)(N7-G)] derivatives being clearly related to their bioavailability. In vivo platination of free purines before their incorporation in nucleic acids therefore opens new perspectives in platinum based antitumour drugs, for a better understanding of both the action mechanism and the new molecular design.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965;205:698–9.
Rosenberg B, Van Camp L, Grimley EB, Thomson AJ. The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes. J Biol Chem 1967;242:1347–52.
Rosenberg B. Biological effects of platinum compounds. New agents for the control of tumors. Platinum Met Rev 1971;15:42–51.
Weiss RB, Christian MC. New cisplatin analogues in development. A review. Drugs 1993;46:360–77.
Wong E, Giandomenico CM. Current status of platinum-based antitumor drugs. Chem Rev 1999;99:2451–66.
Reedijk J. Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell? Chem Rev 1999;99:2499–510.
Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Disc 2005;4:307–20.
Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 1998;34:1522–34.
Benedetti M, Malina J, Kasparova J, Brabec V, Natile G. Chiral discrimination in platinum anticancer drugs. Environ Health Persp 2002;110:779–82.
Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999;99:2467–98.
Fuertes MA, Alonso C, Pérez JM. Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev 2003;103:645–62.
Hromas RA, North JA, Burns CP. Decreased cisplatin uptake by resistant L1210 leukemia cells. Cancer Lett 1987;36:197–201.
Hambley TW. The influence of structure on the activity and toxicity of Pt anticancer drugs. Coord Chem Rev 1997;166:181–223.
Reedijk J. Improved understanding in platinum antitumor chemistry. Chem Commun 1996;7:801–6.
Ano SO, Kuklenyik Z, Marzilli LG. In: Lippert B, ed. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug. Weinheim, Germany: Wiley-VCH, 1999:247–91.
Natile G, Marzilli LG. Non-covalent interactions in adducts of platinum drugs with nucleo-bases in nucleotides and DNA as revealed by using chiral substrates. Coord Chem Rev 2006;250:1315–31.
Isab AA, Marzilli LG. Supermacrochelate complexes containing an artificial nucleic acid backbone and derived from excellent ligands formed by treating platinum anticancer agents with nucleotide triphosphates. Inorg Chem 1998;37:6558–9.
Brabec V, Kasparkova J. DNA interactions of platinum anticancer drugs. Recent advances and mechanisms of action. In: Pérez JM, Fuertes MA, Alonso C, eds. Metal Compounds in Cancer Chemotherapy. Trivandrum, India: Research Signpost, 2005:187–218.
Benedetti M, Saad JS, Marzilli LG, Natile G. Chiral discrimination in the formation reaction and at equilibrium for N,N,N′,N′-tetramethyl-1,2-diaminocyclohexane-PtG2 complexes. Dalton Trans 2003;5:872–9.
Benedetti M, Cini R, Tamasi G, Natile G. Crystal and molecular structure and circular dichroism of [bis-(guanosine-5′-monophosphate (-1) )(N,N,N′,N′-tetramethyl-cyclohexyl-1,2-diamine)platinum(II)] complexes with R,R and S,S configurations of the asymmetric diamine. Chem Eur J 2003;9:6122–32.
Benedetti M, Marzilli LG, Natile G. Rotamer stability in cis-[Pt(diA)G2] complexes (diA = diamine derivative and G = guanine derivative) mediated by carrier-ligand amine stereochemistry as revealed by circular dichroism spectroscopy. Chem Eur J 2005;11:5302–10.
Benedetti M, Tamasi G, Cini R, Marzilli LG, Natile G. The first pure ∧HT rotamer of a complex with a cis-[Metal(nucleotide)2] unit: a cis-[Pt(amine)2(nucleotide)2] ∧HT rotamer with unique molecular structural features. Chem Eur J 2007;13:3131–42.
Van Rompay AR, Johansson M, Karlsson A. Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases. Pharmacol Ther 2003;100:119–39.
Seki S, Hongo A, Zhang B, Akiyama K, Sarker AH, Kudo T. Inhibition of cisplatin-mediated DNA damage in vitro by ribonucleotides. Jpn J Cancer Res 1993;84:462–7.
Benedetti M, Ducani C, Migoni D, et al. Experimental evidence that a DNA polymerase can incorporate N7-platinated guanines to give platinated DNA. Angew Chem Int Ed Engl 2008;47:507–10.
Tasara T, Angerer B, Damond M, et al. Incorporation of reporter molecule-labeled nucle-otides by DNA polymerases. II. High-density labelling of natural DNA. Nucleic Acids Res 2003;31:2636–46.
Holler E, Bauer R, Bernges F. Monofunctional DNA-platinum(II) adducts block frequently DNA polymerase. Nucleic Acids Res 1992;20:2307–12.
Murray V, Motyka H, England PR, et al. The use of Taq DNA polymerase to determine the sequence specificity of DNA damage caused by cis-diamminedichloroplatinum(II), acridine-tethered platinum(II) diammine complexes or two analogues. J Biol Chem 1992;267:18805–9.
Vaisman A, Warren MW, Chaney SG. The effect of DNA structure on the catalytic efficiency and fidelity of human DNA polymerase β on templates with platinum-DNA adducts. J Biol Chem 2001;276:18999–19005.
Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63.
Gray JH, Owen RP, Giacomini KM. The concentrative nucleoside transporter family, SLC28. Eur J Physiol 2004;447:728–34.
Baldwin SA, Beal PR, Yao SYM, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Eur J Physiol 2004;447:735–43.
Rooseboom M, Commandeur JNM, Vermeulen NPE. Enzyme-catalyzed activation of antican-cer prodrugs. Pharmacol Rev 2004;56:53–102.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Benedetti, M. et al. (2009). Possible Incorporation of Free N7-Platinated Guanines in DNA by DNA Polymerases, Relevance for the Cisplatin Mechanism of Action. In: Bonetti, A., Leone, R., Muggia, F.M., Howell, S.B. (eds) Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-459-3_17
Download citation
DOI: https://doi.org/10.1007/978-1-60327-459-3_17
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-458-6
Online ISBN: 978-1-60327-459-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)